Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245790 · ClinicalTrials.gov registry record · Phase 1
A Study of Fostamatinib in Subjects With Impaired Kidney Function
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01245790 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT01245790, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A 2 stage study to evaluate the amount of fostamatinib in the blood and urine in subjects with impaired kidney (renal) function compared with healthy volunteers with normal renal function. Stage 1 will include healthy subjects and subjects with end stage renal disease, while Stage, 2 may include subjects with mild, moderate and/or severe renal impairment dependent on the outcome of Stage 1. The study will also evaluate safety and tolerability in subjects with renal impairment.
Interventions
- DRUG fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245790
The ClinicalTrials.gov registry entry for NCT01245790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fostamatinib is the first listed.
NCT01245790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01245790 about?
NCT01245790 is a clinical study titled "A Study of Fostamatinib in Subjects With Impaired Kidney Function". A 2 stage study to evaluate the amount of fostamatinib in the blood and urine in subjects with impaired kidney (renal) function compared with healthy volunteers with normal renal function. Stage 1 will include healthy subjects and subjects with end stage renal disease, while Stage, 2 may include sub...
What is the current status of trial NCT01245790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01245790?
The interventions under investigation include: fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01245790?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.